Cenegermin-Bkbj
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Observation of Corneal Nerve Regeneration after Oxervate Treatment with Confocal Microscopy - A Clinical Case.
Journal: Klinische Monatsblatter fur Augenheilkunde
Published: March 17, 2026
The Efficacy and Safety of Recombinant Human Nerve Growth Factor (rhNGF) in Patients With Dry Eye Disease: A Systematic Review and Meta-analysis.
Journal: International ophthalmology
Published: August 06, 2025
Topical Cenegermin-Bkbj Dramatically Resolves Neurotrophic Keratitis Associated With Pars Plana Vitrectomy.
Journal: Ophthalmic surgery, lasers & imaging retina
Published: March 14, 2025
Nerve Growth Factor Treatment for Neurotrophic Keratopathy in the IRIS® Registry.
Journal: Ophthalmology
Published: September 25, 2024
Development and Characterization of a Photocrosslinkable, Chitosan-Based, Nerve Growth Factor-Eluting Hydrogel for the Ocular Surface.
Journal: Translational vision science & technology
Published: June 18, 2024
The History of Nerve Growth Factor: From Molecule to Drug.
Journal: Biomolecules
Published: April 09, 2024
Quintessence of currently approved and upcoming treatments for dry eye disease.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
Published: February 13, 2024
Modern capabilities in diagnosis and treatment of neurotrophic keratopathy
Journal: Vestnik oftalmologii
Published: December 27, 2022
Cost and Prescriber and Patient Characteristics of Cenegermin Use in the Medicare Population.
Journal: American journal of ophthalmology
Published: June 30, 2022
Observational study of cenegermin for the treatment of limbal stem cell deficiency associated with neurotrophic keratopathy.
Journal: Therapeutic advances in ophthalmology
Published: March 02, 2022
Last Updated: 06/30/2026